Phase 3 Crohn's Disease and Colitis Trial, Recruiting NCT05923073 Sponsor: Janssen Research & Development, LLC Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 3 Crohn's Disease and Colitis Trial, Recruiting

NCT05923073
Recruiting Phase 3 🇦🇺 Australian site

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • You (or your child) must have been diagnosed with Crohn's Disease (including a type that causes tunnels or tracts, called fistulizing Crohn's Disease), affecting the large intestine, small intestine, or both, confirmed at some point in the past through clinical assessment, a camera examination of the gut, and tissue samples.
  • The Crohn's Disease must currently be moderately to severely active, based on a specific scoring system for children called the Pediatric Crohn's Disease Activity Index (PCDAI), with a score of 30 or higher.
  • A recent camera examination of the gut (within 1 month of starting the study) must show signs of active Crohn's Disease, with a score of 6 or higher on a specific scale (or 4 or higher if the disease only affects the lower part of the small intestine).
  • Previous treatments must not have worked well enough, must have stopped working over time, or must have caused side effects — this includes medications that calm the immune system, steroids (taken by mouth or given through a drip), biologic medicines, or a specific newer type of drug called a JAK inhibitor; OR you/your child must have become dependent on steroids; OR a liquid-only diet (called exclusive enteral nutrition) must not have worked well enough.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • You/your child must not have certain complications of Crohn's Disease, such as narrowings in the gut causing symptoms, short bowel syndrome, or other problems that are likely to need surgery.
  • You/your child must not currently have a pocket of infection (abscess) related to the condition.
  • You/your child must not have had surgery to remove part of the bowel within the last 26 weeks, or any other surgery inside the abdomen within the last 12 weeks before the study begins.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026

Contact this trial

Principal Investigator: Clinical Trial, Janssen Research & Development, LLC

Phone: 844-434-4210

Australian sites

Perth Children's Hospital, Nedlands,
Mater Hospital Brisbane, South Brisbane,
The Children's Hospital at Westmead, Westmead,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
13 March 2024
Est. completion
27 October 2027

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇫🇷 France 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇳🇱 Netherlands 🇳🇴 Norway 🇵🇱 Poland 🇵🇹 Portugal 🇰🇷 South Korea 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Percentage of Participants with Clinical Remission at Week 52; Percentage of Participants Who Achieve Endoscopic Response at Week 52

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov